Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intelligent Medicine Acquisition Corp.IQMD · Entity 11509 | Director | November 04, 2021 | November 04, 2021 |
| SelectQuote, Inc.SLQT · Entity 6791 | Director | November 11, 2025 | November 14, 2025 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intelligent Medicine Acquisition Corp.
Report date November 04, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-11-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-260205) under the heading "Description of Securities--Founder Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like) and subject to certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-260205) under the heading "Description of Securities--Founder Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like) and subject to certain anti-dilution rights and have no expiration date.
SelectQuote, Inc.
Report date November 11, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 363,214 |
Reported balance
After 2025-11-11 transaction · row 1
1 source rowRow 1 · 2025-11-11 · Exercise / conversion · Acquired 52,631 · Balance 363,214 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-11 · Exercise / conversion · Disposed 52,631 · Balance 0 F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F3: The award vested in full on the transaction date shown in Column 3. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2035-11-11 | Direct | 106,250 |
Reported balance
After 2025-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-11 · Grant · Acquired 106,250 · Balance 106,250 F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F4: The award vests in full on the date of the Company's 2026 Annual Meeting of Stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan.
F2: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share.
F3: The award vested in full on the transaction date shown in Column 3.
F4: The award vests in full on the date of the Company's 2026 Annual Meeting of Stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 · Expires 2031-12-07 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Disposition to issuer · Disposed 27,077 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2032-02-03 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-28 · Disposition to issuer · Disposed 20,513 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.94 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 11,459 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.30 · Expires 2034-05-28 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-28 · Disposition to issuer · Disposed 8,011 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-28 · Disposition to issuer · Disposed 9,174 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 2,757 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Director Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.03 · Expires 2026-03-31 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2026 Filed Apr 28, 2026 20:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 9,174 | Not disclosed Strike: $63.68 | Not disclosed |
DisclosureSEC source: 0001670683-26-000002 · form4-04282026_080411.xml · derivative · entry 5 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,174 shares Expires 2035-05-29 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 8,011 | Not disclosed Strike: $51.30 | Not disclosed |
DisclosureSEC source: 0001670683-26-000002 · form4-04282026_080411.xml · derivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,011 shares Expires 2034-05-28 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 11,459 | Not disclosed Strike: $37.94 | Not disclosed |
DisclosureSEC source: 0001670683-26-000002 · form4-04282026_080411.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,459 shares Expires 2033-06-14 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 20,513 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001670683-26-000002 · form4-04282026_080411.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,513 shares Expires 2032-02-03 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:30 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 27,077 | Not disclosed Strike: $6.66 | Not disclosed |
DisclosureSEC source: 0001670683-26-000002 · form4-04282026_080411.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,077 shares Expires 2031-12-07 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than $115 per share (the "Closing Amount"), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 00:26 UTC | SelectQuote, Inc. SLQT · Entity 6791 | GrantRestricted Stock Units · Derivative | 106,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-25-000107 · wk-form4_1763079988.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,250 Underlying: Common Stock, par value $0.01 per share · 106,250 shares Expires 2035-11-11 F1 · security: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F4 · derivative.exercise_date: The award vests in full on the date of the Company's 2026 Annual Meeting of Stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 00:26 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionRestricted Stock Units · Derivative | 52,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-25-000107 · wk-form4_1763079988.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 52,631 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units of SelectQuote, Inc. (the "Company") granted to the recipient pursuant to the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock, par value $0.01 per share. F3 · derivative.exercise_date: The award vested in full on the transaction date shown in Column 3. F3 · derivative.expiration_date: The award vested in full on the transaction date shown in Column 3. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 00:26 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionCommon Stock, par value $0.01 per share | 52,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-25-000107 · wk-form4_1763079988.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:37 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0000950170-25-084944 · ownership.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,077 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:37 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $67.36 | $101,040.00 |
DisclosureSEC source: 0000950170-25-084944 · ownership.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:37 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0000950170-25-084944 · ownership.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:20 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 9,174 | $0.00 Strike: $63.68 | $0.00 |
DisclosureSEC source: 0001415889-25-014992 · form4-05302025_080533.xml · derivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,174 Underlying: Common Stock · 9,174 shares Expires 2035-05-29 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 29, 2026 or the next annual meeting of stockholders. Read SEC document |
| May 20, 2025 Filed May 20, 2025 23:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0000950170-25-075492 · ownership.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,577 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| May 20, 2025 Filed May 20, 2025 23:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $58.43 | $87,645.00 |
DisclosureSEC source: 0000950170-25-075492 · ownership.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| May 20, 2025 Filed May 20, 2025 23:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0000950170-25-075492 · ownership.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2025 Filed Apr 29, 2025 22:34 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-25-011532 · form4-04292025_100418.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,077 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| April 29, 2025 Filed Apr 29, 2025 22:34 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $64.20 | $96,300.00 |
DisclosureSEC source: 0001415889-25-011532 · form4-04292025_100418.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| April 29, 2025 Filed Apr 29, 2025 22:34 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-25-011532 · form4-04292025_100418.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 23:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-25-010422 · form4-04082025_110453.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,577 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 23:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $57.50 | $86,250.00 |
DisclosureSEC source: 0001415889-25-010422 · form4-04082025_110453.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 23:31 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-25-010422 · form4-04082025_110453.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 23:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-25-008515 · form4-03182025_110359.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,077 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 23:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $71.64 | $107,460.00 |
DisclosureSEC source: 0001415889-25-008515 · form4-03182025_110359.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 23:01 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-25-008515 · form4-03182025_110359.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 00:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-25-005594 · form4-02262025_120208.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,577 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 00:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $63.16 | $94,740.00 |
DisclosureSEC source: 0001415889-25-005594 · form4-02262025_120208.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 00:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-25-005594 · form4-02262025_120208.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 02:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-25-003072 · form4-02052025_020237.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,077 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 02:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,500 | $64.57 | $96,855.00 |
DisclosureSEC source: 0001415889-25-003072 · form4-02052025_020237.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 02:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-25-003072 · form4-02052025_020237.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 00:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-25-001452 · form4-01152025_120110.xml · derivative · entry 5 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,577 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 00:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 300 | $67.32 | $20,195.01 |
DisclosureSEC source: 0001415889-25-001452 · form4-01152025_120110.xml · nonDerivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F4 · price: Represents the weighted average share price of an aggregate total of 300 shares sold in the price range of $67.25 to $67.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 00:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 400 | $66.62 | $26,649.00 |
DisclosureSEC source: 0001415889-25-001452 · form4-01152025_120110.xml · nonDerivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $66.16 to $67.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 00:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 800 | $64.95 | $51,957.20 |
DisclosureSEC source: 0001415889-25-001452 · form4-01152025_120110.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 700 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 800 shares sold in the price range of $64.61 to $65.33 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 00:17 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-25-001452 · form4-01152025_120110.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 01:42 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-030181 · form4-12272024_011221.xml · derivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,077 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 01:42 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 100 | $77.61 | $7,761.00 |
DisclosureSEC source: 0001415889-24-030181 · form4-12272024_011221.xml · nonDerivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 01:42 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,400 | $76.92 | $107,689.54 |
DisclosureSEC source: 0001415889-24-030181 · form4-12272024_011221.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 1,400 shares sold in the price range of $76.50 to $77.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 01:42 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-030181 · form4-12272024_011221.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 22:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-028425 · form4-12052024_101217.xml · derivative · entry 7 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,577 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 22:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 300 | $96.05 | $28,814.01 |
DisclosureSEC source: 0001415889-24-028425 · form4-12052024_101217.xml · nonDerivative · entry 6 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F6 · price: Represents the weighted average share price of an aggregate total of 300 shares sold in the price range of $95.89 to $96.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 22:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 300 | $93.76 | $28,127.01 |
DisclosureSEC source: 0001415889-24-028425 · form4-12052024_101217.xml · nonDerivative · entry 5 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F5 · price: Represents the weighted average share price of an aggregate total of 300 shares sold in the price range of $93.18 to $94.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 22:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 200 | $91.91 | $18,381.00 |
DisclosureSEC source: 0001415889-24-028425 · form4-12052024_101217.xml · nonDerivative · entry 4 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F4 · price: Represents the weighted average share price of an aggregate total of 200 shares sold in the price range of $91.59 to $92.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 22:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 400 | $89.84 | $35,937.00 |
DisclosureSEC source: 0001415889-24-028425 · form4-12052024_101217.xml · nonDerivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F3 · price: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $89.39 to $90.13 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 22:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 300 | $88.53 | $26,558.70 |
DisclosureSEC source: 0001415889-24-028425 · form4-12052024_101217.xml · nonDerivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 300 shares sold in the price range of $88.34 to $88.66 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 22:58 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 1,500 | $6.66 | $9,990.00 |
DisclosureSEC source: 0001415889-24-028425 · form4-12052024_101217.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 15, 2024 01:57 UTC | SelectQuote, Inc. SLQT · Entity 6791 | GrantRestricted Stock Units · Derivative | 52,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-24-000108 · wk-form4_1731635826.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,631 Underlying: Common Stock, par value $0.01 per share · 52,631 shares Expires not disclosed F1 · security: Represents restricted stock units (RSUs) of SelectQuote, Inc. (the "Company") granted to Dr. Patel under the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, $0.01 par value per share. F4 · derivative.exercise_date: The RSUs vest on the date of the Company's 2025 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. F4 · derivative.expiration_date: The RSUs vest on the date of the Company's 2025 annual meeting of stockholders (the "Vesting Date"), subject to the recipient's continued service on the Company's Board of Directors as of the Vesting Date. Read SEC document |
| November 12, 2024 Filed Nov 15, 2024 01:57 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionRestricted Stock Units · Derivative | 94,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-24-000108 · wk-form4_1731635826.xml · derivative · entry 2 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 94,890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units (RSUs) of SelectQuote, Inc. (the "Company") granted to Dr. Patel under the Company's 2020 Omnibus Incentive Plan. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, $0.01 par value per share. F3 · derivative.exercise_date: The award vested in full on the transaction date shown in Column 3. F3 · derivative.expiration_date: The award vested in full on the transaction date shown in Column 3. Read SEC document |
| November 12, 2024 Filed Nov 15, 2024 01:57 UTC | SelectQuote, Inc. SLQT · Entity 6791 | Exercise / conversionCommon Stock, par value $0.01 per share | 94,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001794783-24-000108 · wk-form4_1731635826.xml · nonDerivative · entry 1 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:37 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-24-026874 · form4-11142024_091117.xml · derivative · entry 3 Patel Kavita · CIK 0001670683 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,077 Underlying: Common Stock · 1,500 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.